Big Biogen boost on Alzheimer’s news could win back biotech investors
The approval by U.S. regulators on Monday of a Biogen Inc (BIIB.O) drug to treat Alzheimer’s disease could reinvigorate investor interest more broadly in biotech and pharmaceutical shares that have struggled in 2021.
